ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Nephrology

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

7,043Medicare Part D Prescriptions Filled, Including Refills
$559K Total Retail Price of All Prescriptions
192 Patients Receiving at Least One Drug in Part D
71%Patients 65 Years and Older
82% Subsidized Claims for Low-Income Patients

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume .

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category
SIMVASTATIN 318 216
AMLODIPINE BESYLATE 285 253
PANTOPRAZOLE SODIUM 228 182
ALLOPURINOL 225 103
FUROSEMIDE 207 174
RENVELA 157 92
LEVOTHYROXINE SODIUM 141 85
CALCIUM ACETATE 130 46
METFORMIN HCL 128 76
CARVEDILOL 122 99
LISINOPRIL 121 82
GLIMEPIRIDE 108 108
PAROXETINE HCL 106 106
DIOVAN 101 56
CRESTOR 92 50
NEXIUM 92 17
ZOLPIDEM TARTRATE 92 41
GABAPENTIN 92 84
CLONIDINE HCL 89 79
DILTIAZEM ER 88 49
ISOSORBIDE MONONITRATE ER 86 42
OLANZAPINE 85 50
ATORVASTATIN CALCIUM 82 78
PLAVIX 78 74
HYDROCHLOROTHIAZIDE 74 74
BYSTOLIC 72 52
BENICAR 72 21
CLOPIDOGREL 71 70
HYDROCODONE-ACETAMINOPHEN 69 47 S3
WARFARIN SODIUM 68 52
CITALOPRAM HBR 68 0
METOPROLOL SUCCINATE 67 50
TORSEMIDE 64 23
HYDRALAZINE HCL 61 0
NAMENDA 61 55
LOSARTAN POTASSIUM 60 51
PEN NEEDLE 60 38
DONEPEZIL HCL 60 60
SENSIPAR 58 32
TOPIRAMATE 56 0
POTASSIUM CHLORIDE 54 37
OXYCODONE HCL-ACETAMINOPHEN 52 34 S2
DESMOPRESSIN ACETATE 51 0
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 3, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.